Compare DexCom, Inc. (DXCM) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Teladoc Health Inc — how do they compare? DexCom, Inc. trades at $90.37 (market cap $33.79B), while Teladoc Health Inc trades at $6.6 (market cap $1.24B). The key difference: DexCom, Inc. is far larger — about 27.3× Teladoc Health Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Teladoc Health Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | TDOC | |
|---|---|---|
Market Cap | $33.79B | $1.24B |
Sector | Health | Health |
52-Week High | $89.53 | $9.72 |
52-Week Low | $54.84 | $4.47 |
Enterprise Value | $33.24B | $1.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
TDOC trades at $6.66, down 5.93% amid bearish technical signals and negative sentiment following a Q2 2026 revenue miss and lowered full-year guidance. The stock shows weak profitability with a net income margin of -7.13% but trades below book value with a P/B of 0.94. Recent news highlights multiple law firm investigations into potential securities violations, adding to investor concerns.
The outlook remains challenging with revenue pressures in the BetterHelp segment and ongoing losses, though cost controls in Integrated Care provide some support. Analyst consensus is mixed with a $8.88 price target but high hold ratings, indicating cautious optimism amid significant operational and legal risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
